Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

A team made up of researchers from all over the world has developeda new way to store energy by lowering sand into defunct underground mines. The noveltechnique, called Underground Gravity Energy Storage (UGES),presents an effective long-term solution to store energy that makesuse of abandoned mining sites. The researchers stated that thetechnique could be used when the price of electricity was high. Theapproach involves transporting sand into underground mines and thenconverting the soil’s potential energy into electricity through regenerative braking.The researchers explained that when electricity was cheap, the soilcould then be removed from the mine using electric motors into anupper reservoir to store energy. Regenerative braking is amechanism that converts the kinetic energy of a moving object and,in the process of slowing it down, creates energy that can eitherbe stored until needed or used immediately. Such energy-storagemethods could allow the energy sector to extract maximum value fromminerals such as silver produced by numerous miners, including Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF), so that available supplies meet the needs of the energy sectorfor decades to come.

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.

Projects

Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Tuesday's trading session at $2.27, up 0.088183%, on 32,181 volume. The average volume for the last 3 months is 169,682 and the stock's 52-week low/high is $2.09/$4.46.

Recent News

• Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) - Researchers May Have Found a Way to Store Energy Using Abandoned Mines
• Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) CEO, Thomas Larsen, Featured in Interview with Commodity TV During the Mines and More Conference
• MiningNewsBreaks - Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Eyes Opportunity Following Recent Exploratory Work at Its Iska Iska Project

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

The devastating storms wreaking havoc on California have had a wide-ranging negative impact on cannabisbusinesses, disrupting operations and perhaps even supplies. In alast-ditch effort to limit the damage, some cannabis companiestemporarily shut down business and fortified their facilities.Several operators have been unable to reach their operations due toroad closures and hazardous conditions, while numerous poweroutages have halted production and exposed plants to contaminants,such as mold. This is the most recent climate disaster to hit thestate marijuana industry, following a heat wave in September and wildfire season several years earlier. Workers cannot access cultivationfacilities due to washed-out roads, which may result in lost salesand production delays, including those for packaging and flowertrimming. If the current conditions persist, many cannabis retailstore shelves could soon be empty. The challenges Californiacannabis enterprises are facing are just a fraction of the issuesthat the industry has to deal with, such as the hoops companiessuch as India Globalization Capital Inc. (NYSE American: IGC) have to navigate just so they can conduct needed studies on thissubstance.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Tuesday's trading session at $0.415, up 5.063%, on 175,349 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.46/$.

Recent News

• India Globalization Capital Inc. (NYSE American: IGC) - 420 with CNW - Flooding, High Winds Ravage Marijuana Operations in California
• 420 with CNW - AMA Study Finds Patients Are Turning to Marijuana for Pain Management
• New Research Suggests HRT May Reduce Alzheimer's Risk in Women

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices andwearable technology products for remote patient monitoring, islaunching a suite of wearable companion products to its innovativeSmartSole shoe insole units. “The patented GPS-enabled SmartSole isa non-intrusive tracking device designed to monitor the location ofpeople with cognitive memory disorders such as Alzheimer’s Diseasewho tend to get lost or wander. The tech-designed insole may alsobe used by people at risk of kidnapping, such as children,government employees and select professionals. A next-generationshoe insole branded SmartSole plus incorporates biometric sensorspaired with smart analytics to analyze the wearer’s movements forassessing overall health and wellness, and the company’s mostrecent product rollout – the in-home RoomMate system – uses 3Dinfrared motion-sensitive technology to allow caregivers toremotely monitor fall-prone loved ones in an unobtrusive manner,” arecent article reads. “MetAlert is approaching the inflection pointof its growth curve by its ability to sell a multitude of productsand services to a broader audience, which will result in greaterrevenue per user (‘RPU’),” MetAlert CEO Patrick Bertagna is quotedas saying. To view the full article, visit https://ibn.fm/Gr9rl

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.

Products

• GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
  • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
  • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
  • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
  • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
• Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
• RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and InternetStudios.com, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Tuesday's trading session at $0.1948, up 33.0556%, on 52,520 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$1.00.

Recent News

• MetAlert Inc. (OTC: MLRT) - BioMedNewsBreaks - MetAlert Inc. (MLRT) Approaching Inflection Point of Its Growth Curve
• MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna
• MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

• Renewable textile innovator Coyuchi Inc. is dedicated to makingluxury sustainable practice products a central part of the homeliving design industry
• Coyuchi’s President and CEO Eileen Mockus recently participatedin a Bell2Bell podcast interview to discuss companyachievements during 2022 and plans for 2023
• Coyuchi to introduce two new products in 2023 that will usecotton the company helped grow last year through a Californiafarm focused on soil biodiversity and renewable practices
• The company’s Reg A+ investment offering, that was announced inAugust, already topped $1 million milestone in December

Organic luxury bed, bath, and apparel product innovator Coyuchi is celebrating the company’s new impetus for product categorydevelopment and marketing thanks to enthusiasm for its RegulationA+ offering announced in August. “One of the first use of fundsthat we kicked off at the end of 2022 was opening a second retaillocation here in Palo Alto, Calif. … That store launched justbefore all of the holiday selling kicked in along aboutmid-November and (we’re) still focusing on how do we enhance thatcustomer experience,” company President and CEO Eileen Mockus saidduring a recent interview for InvestorBrandNetwork’s The Bell2BellPodcast.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

• A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
• The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
• C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

• Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
• Bath – A luxurious line of towels, bath rugs, and mats.
• Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
• Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

• Coyuchi Inc. - Luxury Bed & Bath Product Designer Coyuchi Inc. Notes Reg A+ Successes and Goals for 2023, in Bell2Bell Podcast
• Coyuchi Inc. CEO Eileen Mockus to Discuss Company’s Regulation A+ Offering During Live Webinar on Monday, January 23, 2023
• InvestorNewsBreaks – Coyuchi Inc. Positioned with Sustainable Products in Trend That’s ‘Here to Stay’

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

• Homes contribute significantly to climate change, producing twiceas much carbon dioxide emissions annually than automobiles

• GeoSolar Technologies’ SmartGreen(TM) Home system utilizes leadingedge solar, geothermal and air filtration technology to offer truenet zero homes that achieve some of the highest HERS index ratingsin the industry

• The company recently published a webinar discussing the industrywhile providing comprehensive insight on SmartGreen(TM) homes, fromfinancial to health

When it comes to greenhouse gases and carbon emissions that arepolluting our atmosphere and contributing to climate change, carsare usually pointed at as the major culprit. That’s not an accurateaccusation, though. As detailed by GeoSolar Technologies (“GST”) in a recent webinar available on YouTube, homes produce far more carbon dioxide thancars do and it’s not even close.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

• Making a real planet-changing difference in reducing air pollution
• Eliminating or significantly reducing homeowners’ future utility bills
• Enjoying lifetime energy independence and protection from price escalation and energy shortages
• Eliminating greenhouse gas emissions from operation of home and daily life
• Increasing home value
• An integrated design for seamless operation of renewable energy systems
• Maintaining a significantly healthier living environment
• Leveraging existing renewable energy tax credits and electrification incentives
• Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News

• GeoSolar Technologies Inc. - Homes Leading Cause of Climate Crisis, GeoSolar Technologies Inc. at Forefront of Home Electrification Trend
• QualityStocksNewsBreaks – GeoSolar Technologies Inc. Delivering SmartGreen(TM) in Dedication to Making Net-Zero a Reality
• InvestorNewsBreaks – GeoSolar Technologies Inc. Reinventing Home Energy Market

Cub Crafters Inc.

The QualityStocks Daily Newsletter would like to spotlight Cub Crafters Inc.

CubCrafters, the leading designer and manufacturer of light-sport,experimental and Part 23 certified backcountry aircraft, is guidedby superior quality, industry-leading innovation and independentthinking. “CubCrafters has changed the face of backcountry aviationby producing and selling seven innovative models of light aircraft.Segmented into three categories – Light Sport Aircraft (‘LSA’),Experimental Builder Assist (‘E/AB’), and Part 23 certifiedaircraft – the models include the Carbon Cub SS, Carbon Cub FX-2,Carbon Cub FX-3, Carbon Cub EX-2, Carbon Cub EX-3, NXCub, andXCub,” reads a recent article. In 2022, the company achievedseveral milestones including welcoming outside investment for thefirst time in its history, following the qualification of itsoffering under the Regulation A+ exemption. The company alsointroduced a new lightweight engine for the E/A-B Carbon Cub seriesof aircraft. “More recently, CubCrafters announced that itsflagship certified CC19 XCub aircraft had been selected by theUnited States Department of Agriculture (‘USDA’) for a newgovernment aircraft-fleet-modernization contract, extending a longworking relationship that began in 2003. CubCrafters CEO PatrickHorgan observed that the long relationship is a ‘strong testamentto our ability to design and manufacture exceptionally ruggedutility aircraft for backcountry missions.’”

To view the full article, visit https://ibn.fm/lXMt0

Cub Crafters Inc. (typically styled CubCrafters) is an OEM aircraft manufacturer based at McAllister Field Airport in Yakima, Washington. The company was founded in 1980 to build parts and supplementary type certificate (STC) improvement modifications, which were used to establish it as the preeminent center for rebuilding the classic Piper PA-18 Super Cub light aircraft. CubCrafters went on to advance the market with its own, newly manufactured aircraft models and holds an approved Federal Aviation Administration (FAA) Production Certificate. Yakima-based operations include an engineering design-test-certification center, aircraft parts and assembly production facilities, and an MRO maintenance service and overhaul facility.

The first newly manufactured aircraft by the company, the CC18-180 Top Cub, was Federal Aviation Administration (FAA) type certified in December 2004. The Top Cub was also granted type certificates (TC) by Transport Canada in July 2008, followed by Australian certification in August of that same year. With the FAA’s release of the new Light Sport Aircraft (LSA) class, CubCrafters created a brand-new model in 2008, the CC11-100 Sport Cub, similarly based on the original Piper J-3 Cub’s appearance, which it validated to ASTM international standards as an LSA. This model advanced to become known as the Carbon Cub, the bestselling LSA of all time in the U.S.

CubCrafters focuses on four main product lines, including the Carbon Cub SS, Carbon Cub FX, XCub, and the Top Cub under license. Some models are built to be lightweight and powerful for quicker flights, while others are built for longer missions in unforgiving backcountry environments.

CubCrafters has a service and overhaul facility for PA-18 Super Cubs and other Cub derivative designs at its Yakima headquarters. The company sells aircraft kits as well as finished aircraft.

Aircraft

The Carbon Cub is available in three variants: Carbon Cub SS (production Light Sport Aircraft), Carbon Cub FX (an innovative Builder Assist E/A-B aircraft) and Carbon Cub EX (E/A-B aircraft kit). Carbon Cub has been designed for off-airport operation with a powerful engine, strong lightweight airframe and nimble low-speed manners. The Carbon Cub has taken the fundamentally superior design of the Piper Super Cub and reinvented it using 21st century materials and computer-aided design. Superior engineering results include the Carbon Cub having 50% fewer parts and weighing more than 300 pounds less than a similarly equipped Super Cub. Now in its third generation of innovation advancements, there are over 1,000 Carbon Cubs flying.

The CubCrafters CC19-180 XCub, FAA Certified and introduced in June 2016, is supplied complete and ready-to-fly. The XCub is a further scaled development of the CubCrafters Carbon Cub, which the company continues to supply, but with higher performance and incorporating more structural carbon fiber. The XCub was developed over a six-year period and not publicly announced until FAA TC had been completed and issued. The process was completed organically using company resources and did not involve any venture capital, loans nor any advanced customer deposits. XCub is built on a wholly original fuselage design. The CNC-milled 4130 chromoly steel frame meets the latest FAA Part 23 certification standards for 2,300-pound gross weight aircraft. XCub’s useful load is as high as 1,084 pounds. Current Part 23 certification requirements ensure this is the strongest Cub ever produced. It can fly farther, providing greater comfort. It is an airplane that has taken the best from the past and, using the very latest in design, material and manufacturing technology, has established a new standard.

The XCub was approved by the FAA for seaplane operations in December 2017. That same month, EASA approved the XCub design and issued a new type certificate. Four international type certificates have been gained: EASA Dec-2017, Canada Feb-2018, Japan April-2018, and Australia Aug-2018.

CubCrafters increased the horsepower of the XCub line in 2019, offering two new models: the CC19-215 FAA Certified version and the CCX-2300 Builder Assist, both powered by the new CC393i 215 HP engine built by Lycoming.

In December 2021, CubCrafters gained FAA Certification of a new nose wheel version of the XCub, branded the NXCub.

Market Overview

According to a 2022 analysis by research firm Expert Market Research (“EMR”), the global ultralight and light aircraft market was valued at $7.63 billion in 2021. The EMR report says the market is expected to grow at a CAGR of 4.5% in the forecast period of 2022-2027 to reach a value of $9.93 billion. Ultralight and light aircraft are small aircraft with on-board pilot (and perhaps passengers) designed for use in recreation, sports, pilot training, aerial surveys, mapping, research and agriculture, humanitarian backcountry access, and special military missions, as well as business and personal travel.

CubCrafters currently enjoys a dominant market share of the rugged adventure airplane market.

Management Team

Patrick Horgan is President and CEO at CubCrafters. Before he assumed that role, he was the company’s Vice President/Director of Engineering & Product Development for three years, when he led the FAA Part 23 type certificate approval and production certificate approval of CubCrafters’ newest flagship, the XCub. Mr. Horgan also directed the breakthrough certification that authorized the use of experimental avionics in FAA-certified production aircraft, a first in aviation history. He brings over 30 years’ aircraft development and manufacturing experience in general aviation, commercial, and military industries. Prior to service at the company, he was the General Manager at WACO Classic Aircraft Corporation in Battle Creek, Michigan, and was the commercial aircraft manager of the Boeing 777 wheel and brake program for Goodrich Aerospace in Troy, Ohio. He was also a designer on the F/A-18 Super Hornet at McDonnell Douglas (now Boeing) in St. Louis, Missouri. Mr. Horgan holds degrees in aeronautical and astronautical engineering from the University of Illinois, and a certificate in Disruptive Strategy from Harvard Business School. He serves as a member of the Board of Directors of the General Aviation Manufacturers Association and on ASTM aircraft standards committees.

Brad Damm is Vice President at CubCrafters. He has overseen CubCrafters’ sales, marketing, and brand management operations since 2018. Since first joining CubCrafters in 2013, Mr. Damm has served as Factory Direct Sales Manager, the Director of Sales Support, the Global Director of Sales, and the Vice President of Sales and Marketing. During his tenure, the company has seen new sales records year after year across all of CubCrafters new aircraft and kit product lines, and the CubCrafters brand has risen to new levels of awareness and respect with aviation consumers worldwide. Prior to joining the company, he served for over 10 years as the Business Development Manager for one of the largest commercial concrete contractors in the Pacific Northwest, driving the sales and revenue growth that allowed the company to expand from a few dozen to hundreds of employees.

Rick Johnson is the Director of Finance at CubCrafters and has been with the company since 2017. He has 27 years of previous experience as controller and CFO for fruit packing and timber operations in the Pacific Northwest. He holds a Bachelor of Science in Business Administration from Central Washington University.

Christopher Matus is Production Manager at CubCrafters and joined the company in 2011. Before taking that post, he held positions as Fabrication Plant Manager, Machine Shop Manager and CNC Machinist for the company. He has also served as a Combat Engineer in the Washington Army National Guard, deploying to Afghanistan and to natural disasters including the 2014 Oso Mudslide.

Justin Jansky is the Administrative Manager at CubCrafters. He joined the company in 2015 and has a demonstrated history of successful collaboration on major FAA type certification projects in the general aviation industry, specifically under 14 CFR Parts 21 and 23. He is responsible for process management, document control, facilitating FAA certification processes, coordination with FAA delegates and documenting compliance testing. He holds a bachelor’s degree in technology and applied design.

Recent News

• Cub Crafters Inc. - CubCrafters Inc. Acquires Summit Aircraft Skis and Celebrates Contract Extension with US Government
• InvestorNewsBreaks – CubCrafters Inc. Merging High Performance, Latest Technology to Bring Unique Perspective to Access the World
• InvestorNewsBreaks – CubCrafters Inc.’s Distinctiveness in Backcountry Aviation Increases Demand for Its Aircraft

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

•Rates of cardiovascular risk factors, disease and heart attacksprojected to increase significantly

•HeartBeam offers a personal, portable and easy-to-use heart-attackdetection solution

•“Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transformthe way patients and doctors detect heart attacks,” states CEO

With heart disease consistently being the leading cause of death inthe United States (https://ibn.fm/kDLwz), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention andsupport. As a cardiac technology company, HeartBeam is leading theway in identifying heart attacks by developing a personal, portableand easy-to-use heart-attack detection solution.HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only3D-vector electrocardiogram (“VECG”) platform for heart attackdetection anytime, anywhere, has appointed Robert Eno to the newlycreated position of president. A senior medical technologyexecutive, Eno will work to enhance the company’s strategic andoperations capabilities. Eno brings a background of almost threedecades experience in developing markets and commercializingdisruptive medical technologies to his new role, where he will beessential in the company’s strategic direction, commercializationefforts, and day-to-day operations. Eno noted that he believesHeartBeam’s technology will be able to make a major impact on thelives of the millions of people who suffer from cardiac-relatedissues. In previous positions, which included CEO of PreviewMedical Inc. and senior VP for Heartflow Inc., Eno has createdgo-to-market strategies for an array of breakthrough productsincluding noninvasive FFR CT (“FFR CT”) diagnostic for coronaryartery disease, laser cataract surgery, scanning retinal laserphotocoagulation and intravascular brachytherapy. He has led allaspects of marketing and product functions for a new category ofpersonalized, noninvasive testing for heart disease and has heldsenior marketing and sales leadership roles at OptiMedica, NeoGuideSystems and Avantec Vascular. “We have a tremendous opportunity toaccelerate our company growth as we move forward on ourcommercialization path, and we’re excited to have Rob join ourleadership team,” said HeartBeam CEO and founder Branislav Vajdic,PhD, in the press release. “Rob has extensive experience bringinginnovative medical technology products to market, which will beinvaluable as we move forward with plans to broaden our productportfolio pipeline.” To view the full press release, visit https://ibn.fm/hQoVc

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

• HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
• HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $4.065, off by 0.245399%, on 70,275 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.12/$6.74.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Names Senior Medical Tech Veteran as New President
• HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space
• BioMedNewsBreaks - HeartBeam Inc.'s (NASDAQ: BEAT) Growing Patent Portfolio Poised to Have Disruptive Effect on Multibillion Markets

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

A study conducted by researchers at Corewell Health East hasrevealed that toddlers and infants have higher chances ofexperiencing severe health outcomes in the face of the so-called “tripledemic,” which is comprised of flu, RSV and COVID. Three years afterCOVID-19 first reared its ugly head, new research found that youngpatients face the risk of severe health outcomes after being infected by multiple respiratory viruses. Theinvestigators, led by Dr. Amit Bahl, found that although omicron cases made up the bulk of hospital admissions for those between the agesof 0 and 17, they weren’t as likely to result in serious or deadlyoutcomes in comparison to the alpha and delta cases. However, thepresence of an additional respiratory virus such as RSV or the flu alongside any of the coronavirus variantssignificantly increased the risk of severe outcomes. Infants andtoddlers were at significantly more risk in the face of multiplerespiratory infections. The growing threat posed by infectiousdiseases has prompted many companies, including BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), to specialize in developing new treatments for these conditionsin both pediatric and adult patients.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

• NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Tuesday's trading session at $2.68, off by 3.2491%, on 200,684 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.37/$22.90.

Recent News

• BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) - Toddlers, Infants Risk Severe Outcomes When Faced with Multiple Infections
• InvestorNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
• BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developingnovel treatments for primary and metastatic cancers in the brainand central nervous system, is enrolling patients in a phase 2trial to evaluate the efficacy of its flagship drug candidate. Thepotentially pivotal trial will evaluate Berubicin for the treatmentof glioblastoma multiforme (“GBM”), an aggressive brain tumor withan average overall survival rate of only 10-12 months. Thecompany’s Chief Executive Officer John Climaco recentlyparticipated in the Virtual Investor “Ask the CEO” Event anddiscussed that enrollment in the trial was approaching 70 patientsagainst a target of 243, a remarkable achievement since it beganabout 14 months earlier. “Patients are a lifeblood of a trial likethis,” Climaco said during the event, as quoted in a recentarticle. “Our target is recurring and refractory GBM patients, andsadly in this deadly cancer, almost everyone will recur. And whenthey do, they do not have any approved treatment option anywhere inthe world… We’ve now offered those patients a chance at achemotherapy that we believe can have efficacy and change theoutcome of this disease.”

To view the full article, visit https://ibn.fm/B5s6v

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $2.29, off by 1.2931%, on 30,175 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.05/$20.10.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses 'Lifeblood' of Phase 2 Berubicin Trial
• Researchers Find That Nutraceuticals May Be Useful in Preventing and Treating Cancer
• Researchers Design a New Way to Kill Cancer Using Cancer Cells

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin and sexual wellness, hasclosed on its previously announced registered direct offering andconcurrent private placement. The offering includes the purchaseand sale of 4,315,787 shares in a registered direct offering, withthe concurrent private placement calling for JUPW to issue and sella total of 8,631,574 warrants to the same investors. The warrantsare to purchase up to one share of common stock each at an exerciseprice of $1 per share. According to the announcement, the privateplacement warrants will be exercisable six months after issuance.The announcement also noted that 4,315,787 warrants have athree-year term beginning from the initial exercise date with4,315,787 warrants having a five-year term from the initialexercise date. The company noted that the purchase price of oneshare, one three-year warrant and one five-year warrant was $0.95.Jupiter Wellness received approximately $4.1 million aggregategross proceeds from both transactions.

To view the full press release, visit https://ibn.fm/0vd8R

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

• Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
• Psoriasis & Vitiligo – Photocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
• Jellyfish Protection Sunscreen – NoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
• Eczema – JW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
• Burns – JW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
• Cold Sores – JW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
• Sexual Wellness – JW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
• COVID-19-Induced Tinnitus – JW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

• Jupiter Wellness Inc. (NASDAQ: JUPW) - InvestorNewsBreaks - Jupiter Wellness Inc. (NASDAQ: JUPW) Closes on $4.1M Direct, Private Placement Offerings
• InvestorNewsBreaks - Jupiter Wellness Inc.'s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record
• InvestorNewsBreaks - Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Correction Regarding $4.1M Registered Direct and Private Placement

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC) has transitioned from the development stage to a full-scaleinternational distributor with operations in over 12 countriesworldwide, achieved under Luis Merchan’s tenure as CEO. “Merchanhas also spearheaded several mergers and acquisitions, most notablyJustCBD and Vessel Brand, which have since set the company up forrapid growth. Flora also secured $34.5 million in financing andsigned deals with key retail distributors such as Tropi, aColombia-based distributor, Walmart and Macy’s. The company alsocompleted its first import of CBD-containing food and beverageproducts into the United States from Colombia under its Mambebrand. It has also signed an agreement with luxury clothing andlifestyle brand Tonino Lamborghini to distribute designer CBDbeverages through this retailer,” a recent article reads. The piecefurther discusses Merchan’s confidence in the company’s strongprogress while working toward market expansion and productdiversification. “Under his leadership, Mr. Merchan is slowlyturning Flora into a global leader in the CBD space while alsohelping it execute its strategy to achieve its short-term andlong-term objectives.” To view the full article, visit https://cnw.fm/K5bS9.

Nearly every state with a legal marijuana market has passed an outright ban on the public consumption of cannabis.Both medical marijuana patients and recreational users are onlyallowed to use cannabis within the confines of their homes, and each state has policies that require consumers to use theircannabis product privately and away from the eyes of the public.Unfortunately, marijuana has an extremely thick and potent smell that tends to linger in spots without proper ventilation and canbe recognized some distance away from the smoker. A Washington, DC,woman whose downstairs neighbor used legal cannabis finally gotsick of the potent smell drifting into her home and took legalaction. According to Josefa Ippolito-Shepherd, cannabis smoke fromher downstairs neighbor constantly drifted up into her retirementhome in Cleveland Park, and try as she might, she just couldn’t getrid of the scent. This lawsuit could have serious ramifications forthe entire marijuana industry, and it is likely that enterprisessuch as Flora Growth Corp. (NASDAQ: FLGC) are keeping tabs on proceedings to know how it pans out.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

• Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
• Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
• Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

• Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
• Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
• Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $0.265, off by 3.8113%, on 751,440 volume. The average volume for the last 3 months is 751,440 and the stock's 52-week low/high is $0.1913/$2.38.

Recent News

• Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - DC Lawsuit May Set New Marijuana Smell Precedent
• CannabisNewsBreaks - Flora Growth Corp. (NASDAQ: FLGC) Working Toward Global Leadership in CBD Space
• 420 with CNW - Federally Funded Research Finds AUD Is Lower in States Where Cannabis is Legal

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

• NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
• BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Tuesday's trading session at $0.0001, even for the day, on 2,547,301 volume. The average volume for the last 3 months is 2.547M and the stock's 52-week low/high is $0.0001/$0.001.

Recent News

• Sugarmade Inc. (OTC: SGMD) - CannabisNewsBreaks - Sugarmade Inc. (SGMD) Leveraging Portfolio Data to Improve Efficiency, Profit Margins, Top-Line Sales
• CannabisNewsBreaks - Sugarmade Inc. (SGMD) Lays Foundation for Significantly Expanded Manufacturing, Distribution Infrastructure
• Sugarmade Inc. (SGMD) Positioning Itself in Space Seeing Growing Government Support